Overview

A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, Phase II trial designed to evaluate the efficacy and safety of PRO95780 when given as a single agent in patients with advanced chondrosarcoma. Up to 90 patients with confirmed chondrosarcoma will be enrolled.
Phase:
Phase 2
Details
Lead Sponsor:
Genentech, Inc.